Closer Look: Cubist Pharmaceuticals' New Antibiotic Contender Print E-mail
By Dr. Amna Sheikh   
Tuesday, 11 November 2014 10:14

Cubist Pharmaceuticals (NASDAQ:CBST) previously announced that new antibiotic Ceftolozane has a new drug application which is being out through the steps by the Food and Drug Administration under a priority review, moreover, the FDA has issued a drug user fee act (PDUFA) date of December 21, 2014.

Cubist Pharmaceuticals is seeking an approval from (FDA) Food and Drug Administration for Ceftolozane/tazobactam that will be used for dealing with complex urinary tract disease and some complex intra abdominal infectivity.


The new drug application is actually supported with 2 fundamental phase three experimental trials of ceftolozane/tazobactam complex for intra abdominal virus and urinary tract disease. These both research studies have met the expectation of both (EMA) European Medicines Agency and Food and Drug Administration (FDA) primary endpoints.  The secondary investigation results are purely supportive of primary result. The experimental trails of ceftolozane/tazobactam have established actions against the problematical gram negative bacteria that may include likes of Pseudomonas aeruginosa and (ESBL) extended spectrum beta lactamase (that produces (E.coli) Escherichia coli and the klebsiella pneumonia) and thus, offers a breakthrough in the management of patients with complex diseases.

Cubist Pharmaceuticals is thus hoping to come up with new cure option to physicians and to address the persistence gram negative virus in patients. This achievement surely is a milestone that emphasizes their worldwide dedication to move ahead in the development of antibiotics to fight with severe health threats to common man.

What is Ceftolozane/Tazobactam?

Ceftolozane/Tazobactam is a new antibiotic contender that is manufactured to cure Gram negative infections. Ceftolozane basically belongs to cephalosporin presently being synthesized with the β-lactamase inhibitor tazobactam for the management of complex urinary tract infections (cUTIs), ventilator-associated bacterial pneumonia and complicated intra-abdominal infections.  Ceftolozane has shown to exhibit strong in vitro action against bacterium known as Pseudomonas aeruginosa.  Tazobactam on the other hand, is a well-known beta-lactamase inhibitor. This is its distinguishing feature.  Ceftolozane/Tazobactam also covers a wide variety of drug-resistant phenotypes for example piperacillin/tazobactam, ceftazidime-resistant isolates, carbapenem, and even some of the strains which are multidrug-resistant (MDR). Ceftolozane shows linear pharmacokinetics unaltered by the tazobactam if it is coadministrated. 

Detail of Gram Negative Bacteria

A lot of infections are being reported all over the world caused by gram negative bacteria. Well adaptive pathogens, they definitely show resistance through many methods.  The gram negative bacteria are regarded as a severe global threat to public health.

About Cubist’s Dedication To Research And Development Of Antibiotic

Cubist Pharmaceuticals has definite concerns to public health and it is helping people all over the world by discovering, developing and commercializing new antibiotics to battle against the infections. These antibiotics offer cure for severe life-threatening viruses as well as diseases caused by a wide range of bacteria. They are striving hard to bring all-inclusive approaches to doctors, to patients, and to the globe—strategies that can outpace imperative bacterial risks of today and plan for the dangers of tomorrow.

"Featured Content" profiles are meant to provide awareness of these companies to investors in the small-cap and growth equity community and should not in any way come across as a recommendation to buy, sell or hold these securities. BiomedReports is not paid or compensated by newswires to disseminate or report news and developments about publicly traded companies, but may from time to time receive compensation for advertising, data, analytics and investor relation services from various entities and firms. Full disclosures should be read in the 'About Us Section'.

Add this page to your favorite Social Bookmarking websites
Digg! Reddit!! Mixx! Google! Live! Facebook! Technorati! StumbleUpon! MySpace! Yahoo!